Form 4: Axogen Director Joseph Tyndall Receives Annual Equity Grant

Axogen, Inc. Director Joseph A. Tyndall was granted 14,150 restricted stock units valued at $150,000 as part of his annual equity compensation.

Summary

• Joseph A. Tyndall, a Director of Axogen, Inc. (AXGN), was granted 14,150 Restricted Stock Units (RSUs).
• The grant was made on June 19, 2025, as an annual equity grant for his service on the Axogen, Inc. Board of Directors.
• Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.
• The number of shares granted is based on a $150,000 valuation as of the grant date.
• The RSUs are scheduled to vest on June 19, 2026, which is the one-year anniversary of the grant date.
• Following this transaction, Joseph A. Tyndall beneficially owns 14,150 derivative securities (RSUs) and 14,150 shares of common stock underlying these RSUs.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the grant aligns the director's interests with shareholders, which is generally viewed favorably. It is a routine compensation event, not indicative of significant operational changes or financial performance.

Positives

• The equity grant aligns Director Joseph A. Tyndall's interests with those of Axogen, Inc. shareholders, as the value of his compensation is tied to the company's stock performance.
• Annual equity grants are a standard practice for compensating board members, promoting long-term commitment and strategic oversight.

Future Outlook

The document indicates that the granted Restricted Stock Units are scheduled to vest on June 19, 2026, contingent on continued service.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specifically an equity grant to a director. Such grants are common practice across industries for compensating board members and aligning their interests with shareholders, particularly in the healthcare and biotechnology sectors where long-term strategic vision is crucial.

Comparison to Industry Standards

• The grant of restricted stock units as part of director compensation is a widely accepted practice across publicly traded companies, including those in the medical device and biotechnology sectors like Axogen, Inc.
• The valuation of the grant ($150,000) and the one-year vesting period are within typical ranges for annual director equity compensation, comparable to practices at similar-sized companies in the healthcare industry.

Corporate Governance

Related Party Transactions

• The grant of Restricted Stock Units to Joseph A. Tyndall, a Director of Axogen, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial interests with the company's performance, potentially fostering decisions that benefit long-term shareholder value.
• Employees: No direct impact on employees is indicated by this specific filing, though director compensation practices can indirectly influence overall corporate culture and compensation philosophies.

Next Steps

• The 14,150 Restricted Stock Units are expected to vest on June 19, 2026, converting into shares of Axogen, Inc. common stock.

Key Dates

Keywords

Axogen, AXGN, Form 4, Restricted Stock Units, RSU, Equity Grant, Director Compensation, Insider Transaction, Corporate Governance